妊娠合并1型糖尿病孕妇在家使用妊娠专用区域模型预测控制闭环系统:单臂观察性多中心研究
本研究纳入10例使用胰岛素泵的妊娠合并1型糖尿病孕妇,评估家用妊娠专用闭环胰岛素输注系统(CLC-P)的可行性与性能。与导入期相比,目标范围内(63-140 mg/dL)时间百分比增加14.1个百分点(64.5% vs 78.6%,P=0.002)。结论认为在家延长使用CLC-P直至分娩是可行的,但需更大规模随机研究进一步评估系统疗效和妊娠结局。
要点
- 10例孕妇在家使用妊娠专用闭环系统,目标范围内时间较导入期增加14.1个百分点(64.5% vs 78.6%,P=0.002)。
- 高血糖(>140 mg/dL)时间及低血糖(<63 mg/dL和<54 mg/dL)时间均显著减少(P=0.033和P=0.037)。
- 9例参与者在CLC-P使用期间目标范围内时间超过共识目标的70%。
核心结论
- 结果表明,在家延长使用CLC-P直至分娩是可行的。
- 需要更大规模的随机研究来进一步评估系统疗效和妊娠结局。
研究设计与样本
- 单臂、观察性、多中心研究。
- 纳入10例使用胰岛素泵的妊娠合并1型糖尿病孕妇,在妊娠中期或早晚期妊娠纳入。
- 在导入期收集个人泵治疗数据并经过2天监督培训后,参与者在家中使用基于智能手机的闭环系统(CLC-P),白天目标80-110 mg/dL,夜间目标80-100 mg/dL,期间饮食和活动不受限制。
主要发现
- 与导入期相比,目标范围63-140 mg/dL内时间百分比平均增加14.1个百分点,相当于每天3.4小时(导入期64.5±16.3% vs CLC-P 78.6±9.2%;P=0.002)。
- CLC-P使用期间,超过140 mg/dL的时间显著减少(P=0.033)。
- CLC-P使用期间,低于63 mg/dL和低于54 mg/dL的低血糖范围时间均显著减少(两者P=0.037)。
- 9例参与者在CLC-P使用期间目标范围内时间超过共识目标70%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大规模的随机研究来进一步评估系统疗效和妊娠结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There are no commercially available hybrid closed-loop insulin delivery systems customized to achieve pregnancy-specific glucose targets in the U.S. This study aimed to evaluate the feasibility and performance of at-home use of a zone model predictive controller-based closed-loop insulin delivery system customized for pregnancies complicated by type 1 diabetes (CLC-P). RESEARCH DESIGN AND METHODS: Pregnant women with type 1 diabetes using insulin pumps were enrolled in the second or early third trimester. After study sensor wear collecting run-in data on personal pump therapy and 2 days of supervised training, participants used CLC-P targeting 80-110 mg/dL during the day and 80-100 mg/dL overnight running on an unlocked smartphone at home. Meals and activities were unrestricted throughout the trial. The primary outcome was the continuous glucose monitoring percentage of time in the target range 63-140 mg/dL versus run-in. RESULTS: Ten participants (HbA1c 5.8 ± 0.6%) used the system from mean gestational age of 23.7 ± 3.5 weeks. Mean percentage time in range increased 14.1 percentage points, equivalent to 3.4 h per day, compared with run-in (run-in 64.5 ± 16.3% versus CLC-P 78.6 ± 9.2%; P = 0.002). During CLC-P use, there was significant decrease in both time over 140 mg/dL (P = 0.033) and the hypoglycemic ranges of less than 63 mg/dL and 54 mg/dL (P = 0.037 for both). Nine participants exceeded consensus goals of above 70% time in range during CLC-P use. CONCLUSIONS: The results show that the extended use of CLC-P at home until delivery is feasible. Larger, randomized studies are needed to further evaluate system efficacy and pregnancy outcomes.
引用
- Levy CJ, Kudva YC, Ozaslan B, et al. At-Home Use of a Pregnancy-Specific Zone-MPC Closed-Loop System for Pregnancies Complicated by Type 1 Diabetes: A Single-Arm, Observational Multicenter Study. Diabetes Care. 2023. PMID: 37196353. doi:10.2337/dc23-0173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。